One hundred and four male patients hospitalized for the first time with the diagnosis of first-episode schizophrenia were comprehensively assessed on admission and discharge. Psychopathology, treatment response, and remission rates were evaluated (based on the Positive and Negative Syndrome Scale (PANSS), severity of symptoms only). On admission, the most frequently observed symptoms were lack of judgment and insight (87.6%), suspiciousness/feelings of persecution (82.3%), delusions (77%), poor attention (70%), disturbance of volition (65.4%), conceptual disorganization (64.7%), and active social avoidance (64%). Except for delusions and hallucinations, the positive items of the PANSS correlated significantly with negative symptoms, and conceptual disorganization correlated with the greatest number of negative symptoms. Individual negative symptoms were present in about half the patients. At discharge, the most frequent symptoms were again lack of judgment and insight (in 55.7%), and for negative symptoms they were blunted affect (22.1%), emotional withdrawal (21.2%), and passive/apathetic social withdrawal (19.5%). The positive symptoms of suspiciousness/feelings of persecution and grandiosity persisted in 20.6% of patients. On average, all symptoms were significantly reduced 44 days after admission. The negative symptoms improved less, compared with the positive ones. At discharge there was a high rate of responders (response defined as minimal 30% reduction of total PANSS): 73% and 74% of patients fulfilled the criteria for remission. On admission, the responders (n = 76) had significantly higher scores of most symptoms, both positive and negative ones than nonresponders (n = 28).

Department of Psychiatry Masaryk University and Faculty Hospital Brno Czech Republic

See more in PubMed

Awad AG. Prediction research of neuroleptic treatment outcome in schizophrenia – state of the art 1978–1993. In: Gaebel W, Awad AG, editors. Prediction of neuroleptic treatment outcome in schizophrenia. Concepts and methods. Wien: Springer-Verlag; 1994. pp. 1–14.

Bradford DW, Perkins DO, Lieberman JA. Pharmacological management of first-episode schizophrenia and related nonaffective psychoses. Drugs. 2003;63:2265–83. PubMed

Češková E, Drybčák P, Lorenc M. Biological markers and possibilities for predicting therapeutic results in schizophrenia. A methodological contribution. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:683–91. PubMed

Emsley RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study Risperidone Working Group. Schizophr Bull. 1999;25:721–9. PubMed

Gitlin M, Nuechterlen K, Subotnik KL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry. 2001;158:1835–42. PubMed

Kane JM, Leucht S, Carpenter D, et al. Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry. 2003;64(Suppl 12):5–19. Introduction: methods, commentary, and summary. PubMed

Kay S, Fiszbein A, Opler LA. The positive and negative syndrome scale for schizophrenia. Schizophr Bull. 1987;13:261–78. PubMed

Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment – naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology. 2003;28:995–1003. PubMed

Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003;160:1396–404. PubMed

McEvoy JP, Hogarthy GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry. 1991;48:739–45. PubMed

Oosthuizen P, Emsley R, Turner JH, et al. A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis. Int J Neuropsychopharmacol. 2004;7:121–31. PubMed

Peralta V, Cuesta MJ, Marinez-Larrea A, et al. Differentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naive patients before and after treatment. Am J Psychiatry. 2000;157:1461–6. PubMed

Remington G, Kapur S, Zipursky RB. Pharmacotherapy of first-episode schizophrenia. Br J Psychiatry. 1998;172(Suppl 33):66–70. PubMed

Sanger TM, Lieberman JA, Tohen M, et al. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry. 1999;156:79–87. PubMed

Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychcotic. J Clin Psychiatry. 2003;64:663–7. PubMed

Brain functional connectivity of male patients in remission after the first episode of schizophrenia

One-year follow-up of patients with first-episode schizophrenia (comparison between remitters and non-remitters)